[go: up one dir, main page]

WO1993013806A1 - Inactivation de medicaments cytotoxiques - Google Patents

Inactivation de medicaments cytotoxiques Download PDF

Info

Publication number
WO1993013806A1
WO1993013806A1 PCT/GB1993/000040 GB9300040W WO9313806A1 WO 1993013806 A1 WO1993013806 A1 WO 1993013806A1 GB 9300040 W GB9300040 W GB 9300040W WO 9313806 A1 WO9313806 A1 WO 9313806A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
component
inactivating
cytotoxic
antibody
Prior art date
Application number
PCT/GB1993/000040
Other languages
English (en)
Inventor
Kenneth Dawson Bagshawe
Original Assignee
Kenneth Dawson Bagshawe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenneth Dawson Bagshawe filed Critical Kenneth Dawson Bagshawe
Priority to GB9410237A priority Critical patent/GB2276624B/en
Priority to EP93901821A priority patent/EP0620742A1/fr
Priority to JP5512252A priority patent/JPH07506339A/ja
Publication of WO1993013806A1 publication Critical patent/WO1993013806A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • This invention relates to cytotoxic drug therapy and, more specifically, to the inactivation of cytotoxic drugs to limit their undesirable side effects. 5
  • cytotoxic therapeutic agents are their lack of discrimination between cancer cells and normal replicating cells which are essential for normal tissue integrity and body function.
  • the effects of cytotoxic agents on these normal tissues limits the dosage of cytotoxic therapy 10 or the duration of its administration. Cytotoxic drug therapy is therefore interrupted at frequent intervals to allow normal tissue recovery. Such interruption also allows recovery of surviving cancer cells and may be important in allowing the emergence of drug resistance.
  • the duration of drug free intervals in therapy usually exceeds the duration of cytotoxic agent administration. This applies to all forms of cytotoxic therapy but is particularly evident in the case of those agents that interfere with DNA replication during S phase of the cell cycle.
  • ADPT Antibody-Directed Enzyme Pro-drug Therapy
  • the enzyme in the conjugate is matched by a subsequently administered prodrug which is a relatively non-toxic substance and is a substrate for the enzyme, the end- product of the reaction being an active cytotoxic drug which is able to diffuse through the tumour and reach cells that do not express the target antigen.
  • the objective of an antibody-enzyme pro-drug approach is to confine the action of cytotoxic agents to tumour sites. This would be advantageous in allowing a greater concentration of drug to act at tumour sites without incurring greater toxic effects on normal tissues. Also, many cytotoxic drugs currently in use are carcinogenic and survivors from one cancer may succumb to a cancer induced by treatment of the former cancer through the effect of the drugs or radiation on normal tissues; restricting mutagenic drugs to cancer sites would reduce this risk of iatrogenic cancer.
  • a method of treatment in which an active cytotoxic drug is generated from a less toxic pro-drug by catalytic action can only achieve the objective, as defined, if the catalyst is confined to the target site(s).
  • an antibody or fragment thereof, or a conjugate comprising an antibody or fragment thereof and an enzyme is injected into a host bearing a tumour which expresses on the cell surface an antigen corresponding to the antibody, the antibody or conjugate preferentially localises at tumour sites. That is to say, the concentration of enzyme at tumour sites is likely to be higher than in other tissues after an interval of hours or days. However, most of the administered antibody or conjugate is retained in other tissues, including the blood to some extent.
  • the enzyme returning to blood can, for instance, be inactivated by a slow infusion of anti-enzyme antibody.
  • accelerated clearance and inactivating methods make antibody enzyme pro-drug therapy widely applicable, some active drug still enters the vascular compartment and reaches cell renewal tissues, particularly the haemopoietic tissues, and can be dose limiting. Where a tumour is relatively large a significant amount of active drug will enter the blood by direct diffusion, or via the lymphatic chain, in addition to any active drug formed by residual enzyme activity in normal tissues.
  • cytotoxic agent can be restricted to those sites where the specific enzyme is located and predominantly to cancer sites.
  • a cytotoxic drug generated anywhere in the body diffuses through the extracellular fluid and is able to reach nearby cells which do not express the marker antigen to which the antibody is directed. It may also pass back into the vascular compartment and then be conveyed to cell renewal tissues. If the tumour mass is large and if the drug has a half-life of more than a few seconds then effects on normal tissues may still prove dose-limiting.
  • Anti-tumour antibodies exist which show little or no binding to haemopoietic tissue, but since haemopoiesis occurs within capillaries, or in proximity to fenestrated capillaries, haemopoietic cells are highly vulnerable to the action of cytotoxic agents present in blood.
  • This blood-mediated effect can be limited by ensuring that the active drug has a short half-life (Bagshawe 1987).
  • a drug generated at any point in the body can reach, via the circulating blood, any other tissue within 20-30 seconds.
  • Some valuable cytotoxic agents possess relatively long half-lives and in the absence of an additional mechanism they may be excluded from consideration.
  • a further consideration is that a very short half-life may limit the concentration of active drug that can be achieved at sites within a tumour mass that are remote from sites of antigen expression and therefore of active drug generation.
  • the objective of the present invention is to inhibit, at least partially, in the blood any active drug which is present in blood, whether it has been generated in blood, or gains access to the blood, from the tumour or normal tissue.
  • One aspect of the present invention provides a compound comprising a portion capable of at least partly restraining the compound from leaving the vascular compartment of a host when said compound is administered to the vascular compartment and an inactivating portion capable of converting a cytotoxic agent into a less toxic substance.
  • the method used to retain an inactivating agent in the vascular compartment will be determined in part by the nature of the inactivating agent which in turn may be determined by the nature of the active drug.
  • the retaining component must be biologicall compatible with all the functions of blood and the body's organs and should be biodegradable although degradation may take place slowly. It is a requirement that entry of the retaining component into tumour extracellular should be minimal. It follows from the latter requirement that the inactivating portion should not be released in a free state from the retaining portion unless the free inactivating portion is rapidly removed from the blood thus limiting its access to tumour extracellular space.
  • the restraining portion may be a red blood corpuscle.
  • the compound may be contained on or within red blood corpuscles by utilising techniques known in the art for causing molecules to enter into red blood corpuscles.
  • the inactivating portion may be attached to the erythrocyte membrane or may be made to enter the erythrocyte and be retained therein.
  • a method of introducing desired agents into mammalian red blood cells without unacceptable loss of cell contents has been described (US 4931276 incorporated herein by reference).
  • This method comprises (a) suspending and incubating the cells in a solution containing a compound which readily diffuses into and out of the cells, the concentration of the compound being sufficient to cause diffusion into the cells so that the contents of the cells become hypertonic; (b) rapidly creating a trans-membrane osmotic gradient by diluting the solution containing the hypertonic cells with an isotonic aqueous medium in the presence of at least one agent to be introduced to cause diffusion of water into the cells with consequent swelling and increase in permeability of the outer membranes; and (c) maintaining the increase in permeability of the membranes for a time sufficient only to permit transport of the agent into the cells and diffusion of said compound out of the cells.
  • This method is especially useful with the "osmotic pulse" mechanism of US4478824 for loading the cells.
  • US4652449 (incorporated herein by reference) describes a further method for encapsulation of a biologically-active substance in mammalian erythrocytes which comprises (a) continuously feeding an aqueous suspension of erythrocytes into the main compartment of a dialysis unit, the second compartment of which contains an aqueous solution which is hypotonic with respect to the erythrocyte suspension so as to cause lysis of the erythrocytes and (b) causing the erythrocyte lysate to be in contact or contacted with the biologically active compound(s) and then resealing the erythrocyte membranes by increasing the oncotic and/or osmotic pressure of the lysate.
  • the restraining portion may be a liposome, or a high molecular weight ( > 25,000 Daltons, preferably at least 40.000 Daltons) polymer such as dextran. or a protein such as macroglobulin.
  • Liposomes with prolonged circulation times are also potential carriers for the inactivating portion. Liposomes with prolonged circulation times have been constructed in various ways. These include the use of ganglioside GM 1. or a mixture of sphingomyelin, egg phosphatidylcholine and cholesterol, or other relatively rigid carrier lipids. For each type of liposome, optimisation by sizing is also desirable to optimise prolonged intravascular residence. Gabizon and Papahadjopoulos (1988) Proc. Nad. Acad. Sci. USA 85, 6949-6953) found a mean particle diameter of 100 nm to be optimal. However, liposomes with a prolonged circulation time are suitable only if they show no significant uptake in tumours.
  • Dextrans are polysaccharides consisting of o--D-glucose units joined predominantly by 1-6 linkages. Partially hydrolysed and fractionated dextran has been widely used as a blood plasma expander. They are cleared by dextranases which are present in the liver, spleen, kidney, intestinal mucosa and colon (Rosenfeld et al (1959) Biokhimia [Engl] 24, 965-970; Ammon (1963) Enz mologia 25, 245-251 ; Serry & Hehre (1956) J. Bacteriol. 71, 373- 380). Dextrans are widely available with mean molecular weights of 40 kD (Gentran 40.
  • Rheomacrodex 70-75 kD (Gentran 70 Macrodex) and 110 kD. They are potentially antigenic and some people have pre-existing antibodies, but reactions to dextrans are reported to be no higher than to other widely used pharmaceutical agents and are mild in character (Goodman and Gilman. The Pharmacological Basis of Therapeutics. 8th Edition. Pergamon Press. New York, Oxford, 1990).
  • polymeric drug carriers have been developed from carbohydrates, peptides and lipids. Some of these may be suitable alternative restraining portions for the inactivating portion provided they fulfil the criteria defined here.
  • the restraining portion may advantageously have a negative charge and may have low lipophilicity.
  • the restraining portion is biodegradable.
  • biodegradable we mean that the retaining portion is degraded in the body of the patient, and therefore has a relatively short half-life, for example less than 72 hours, preferably less than 48 hours.
  • a second aspect of the present invention provides a method of inactivating a cytotoxic agent in the vascular compartment of a host comprising administering to the host said compound.
  • the active drug is an alkylating agent and the method of intravascular inactivation is by reaction with reduced glutathione, a reaction which is catalysed by glutathione-S-transferase.
  • the non-protein thiol glutathione is regarded as the main endogenous reducing agent. Both glutathione and glutathione-S-transferase are present in normal erythrocytes. and it has been shown that glutathione levels in erythrocytes correlate with responses to conventional chemotherapeutic agents in patients with breast cancer, high levels being associated with poor response (Herbergs et al (1992) The Lancet 339. 1074-6).
  • glutathione content of erythrocytes can be substantially increased (3- to 4-fold) by a procedure of hypertonic dialysis and isotonic resealing (Fazi et al (1991) Biotech and App. Biochemistry 14. 60-68).
  • antibodies which discriminate between an active drug and its pro-drug are administered. Since a pro-drug, usually, possesses a cleavable moiety which is not present in the active drug, this provides a structural difference between the pro-drug and drug such that the said antibodies can bind only to the drug.
  • Monoclonal antibodies have the advantage that they can be humanized thereby limiting their immunogenicity. Such an antibody needs to be retained within the vascular compartment since it would otherwise inactivate active drug at tumour sites. Restriction to the vascular compartment may be achieved by galactosylating the antibody which confers a short half-life through uptake by hepatocyte galactose receptors (Sharma et al (1990) Brit. J. Cancer 61, 659- 662). The more galactose moieties on the antibody the shorter the half-life. The short plasma half-life limits tissue penetration but to be effective would require continuous intravenous infusion throughout the period of active drug generation.
  • antibody may be conjugated to a slowly biodegradable polysaccharide such as a dextran.
  • an enzyme which degrades the active drug, or renders it unable to cross cell membranes, and which has no effect, or much less effect, on the pro-drug is administered-
  • an inactivating enzyme compared to an inactivating antibody since one enzyme molecule may inactivate a large number of active drug molecules whereas an antibody would act stoichiometrically (ie one antibody is required to inactivate one active drug molecule).
  • a non-human enzyme has the disadvantage of being immunogenic and therefore requires some form of immunological control but human enzymes including glucuronidases, kinases, sulphatases and other drug-inactivating enzymes may be used depending on the active drug substrate. Humanized catalytic antibodies would be advantageous.
  • An enzyme may be incorporated into erythrocytes by the osmotic technique described herein for the inco ⁇ oration of glutathione, or inco ⁇ orated in liposomes with prolonged circulation time.
  • an enzyme may be retained within the vascular compartment by conjugation to one of the many types of slowly biodegradable polymeric drug carrier (Krinick & Kopecek (1991) in Targeted drug delivery, pp 105-179 (Ed. R.L. Juliano), Springer Verlag New York).
  • a third aspect of the present invention provides a three component kit of parts comprising a first component comprising a target cell-specific portion and an enzymatically active portion capable of converting a pro-drug into a cytotoxic drug; a second component that is a pro-drug convertible by said enzymatically active portion to the cytotoxic drug; and a third component comprising a portion capable of at least partly restraining the component from leaving the vascular compartment of a host when said compound is administered to the vascular compartment, and an inactivating portion capable of converting the cytotoxic drug into a less toxic substance at non-target cell sites.
  • the action of the cytotoxic agent may be sustained at tumour sites for significantly longer periods than is possible by conventional therapy, such that the clinical usefulness of the drug is substantially increased.
  • a cytotoxic agent is generated at target cell sites, whereas any drug which reaches the vascular compartment is at least partially destroyed or inactivated, thereby allowing prolonged action of the cytotoxic agent.
  • the entity which is recognised by the target cell-specific portion of the first component of the kit of parts may be any suitable entity which is expressed by tumour cells, virally-infected cells, pathogenic microorganisms, cells introduced as part of gene therapy or normal cells of the body which one wishes to destroy for a particular reason.
  • the entity must be present or accessible to the targeting portion in significantly greater concentrations in or on cells which are to be destroyed than in any normal tissues of the host that cannot be functionally replaced by other therapeutic means.
  • Tumour-specific antigens when they are expressed on the cell membrane or secreted into tumour extra-cellular fluid, lend themselves to the role of targets for antibodies.
  • the term "tumour” is to be understood as referring to all forms of neoplastic cell growth, including tumours of the lung, liver, skin, pancreas, colon, prostate, uterus or breast.
  • the host is preferably a mammal, most preferably a human, but could in principle be any vertebrate.
  • the antigen-specific portion may be an entire antibody (usually, for convenience and specificity, a monoclonal antibody), a part or parts thereof (for example an Fab fragment or F(ab') 2 ), a single chain antibody fragment or a synthetic antibody or part thereof.
  • the antibody component may be human or humanised or may be a catalytic antibody.
  • a conjugate comprising only part of an antibody may be advantageous by virtue of better tumour penetration and may be less likely to undergo non-specific binding due to the Fc part.
  • Suitable monoclonal antibodies to selected antigens may be prepared by known techniques, for example those disclosed in "Monoclonal Antibodies: A manual of techniques", H.
  • Bispecific antibodies may be prepared by cell fusion, by reassociation of monovalent fragments or by chemical cross-linking of whole antibodies, with one part of the resulting bispecific antibody being directed to the cell-specific antigen and the other to the enzyme.
  • the bispecific antibody can be administered bound to the enzyme or it can be administered first, followed by the enzyme.
  • variable heavy (V H ) and variable light (V L ) domains of the antibody are involved in antigen recognition, a fact first recognised by early protease digestion experiments. Further confirmation was found by "humanisation" of rodent antibodies. Variable domains of rodent origin may be fused to constant domains of human origin such that the resultant antibody retains the antigenic specificity of the rodent parented antibody (Morrison et al (1984) Proc. Nad. Acad. Sci. USA 81, 6851-6855).
  • variable domains that antigenic specificity is conferred by variable domains and is independent of the constant domains is known from experiments involving the bacterial expression of antibody fragments, all containing one or more variable domains.
  • variable domains include Fab-like molecules (Better et al (1988) Science 240. 1041); Fv molecules (Skerra et al (1988) Science 240. 1038): single-chain Fv (ScFv) molecules where the V H and V L partner domains are linked via a flexible oligopeptide (Bird et al (1988) Science 242. 423 : Huston et al (1988) Proc. Natl. Acad. Sci. USA 85.
  • ScFv molecules we mean molecules wherein the V H and V L partner domains are linked via a flexible oligopeptide.
  • antibody fragments rather than whole antibodies
  • the smaller size of the fragments may lead to improved pharmacological properties, such as better penetration of solid tissue.
  • Effector functions of whole antibodies, such as complement binding, are removed.
  • Fab, Fv, ScFv and dAb antibody fragments can all be expressed in and secreted from E. coli. thus allowing the facile production of large amounts of the said fragments.
  • IgG class antibodies are preferred.
  • the entity which is recognised may or may not be antigenic but can be recognised and selectively bound to in some other way.
  • it may be a characteristic cell surface receptor such as the receptor for melanocyte-stimulating hormone (MSH) which is expressed in high numbers in melanoma cells.
  • MSH melanocyte-stimulating hormone
  • the cell-specific portion may then be a compound or part thereof which specifically binds to the entity in a non-immune sense, for example as a substrate or analogue thereof for a cell-surface enzyme or as a messenger.
  • VDEPT virus-directed enzyme-pro-drug therapy
  • a difference in transcription between cells may be associated with tissue-specific promoters, or may be due to changes in activator or repressor molecules in the neoplastic state.
  • liver-associated albumin transcriptional regulatory sequences may be useful to drive the expression of inhibitor-inactivating enzymes in the treatment of patients with hepatocellular carcinoma. More transcriptional differences between normal and neoplastic cells are being discovered all the time, and it is believed that many of these differences may be exploited in the methods of the present invention.
  • Recombinant, replication-defective retroviruses which are suitable for delivering the genetic constructs (ie promoter plus gene encoding inhibitor-inactivating enzyme) to target cells have been disclosed (Huber et al (1991) Proc. Natl. Acad. Sci. USA 88, 8039-8043).
  • the first component of the kit may be a system for delivering a suitable genetic construct for VDEPT.
  • tumour-associated antigens and antibodies or antibody fragments directed at carcinoembryonic antigen (CEA) and antibodies or their fragments directed at human chorionic gonadotrophin (hCG) can be conjugated to carboxypeptidase G2 and the resulting conjugate retains both antigen binding and catalytic function. Following intravenous injection of these conjugates they localise selectively in tumours expressing CEA or hCG respectively. Other antibodies are known to localise in tumours expressing the corresponding antigen. Such tumours may be primary and metastatic colorectal cancer (CEA) and choriocarcinoma (hCG) in human patients or other forms of cancer.
  • CEA carcinoembryonic antigen
  • hCG human chorionic gonadotrophin
  • antibody-enzyme conjugates may also localise in some normal tissues expressing the respective antigens, antigen expression is more diffuse in normal tissues.
  • Such antibody-enzyme conjugates may be bound to cell membranes via their respective antigens or trapped by antigen in interstitial space.
  • Carcino-embryonic ⁇ C46 (Amersham) Imaging & Therapy of colon Antigen (85A12 (Unipath) /rectum tumours.
  • Placental Alkaline H17E2 (ICRF. Imaging & Therapy .of Phosphatase Travers & Bodmer) testicular and ovarian cancers.
  • Pan Carcinoma NR-LU-10 (NeoRx Imaging & Therapy of Co ⁇ oration) various carcinomas incl. small cell lung cancer.
  • HMFG1 Polymo ⁇ hic HMFG1 (Taylor- Imaging &. Therapy of Epithelial Mucin Papadimitriou. ovarian cancer, pleural (Human milk fat ICRF) effusions. globule)
  • CPG2 j8-human Chorionic W14 Targeting of enzyme
  • antigens include alphafoetoprotein. Ca-125 and prostate specific antigen.
  • CD3 Surface Antigen
  • B-lymphocyte RFB4 Janossy. Immunotoxin therapy of B Surface Antigen Royal Free cell lymphoma. (CD22) Hospital
  • Pan T lymphocyte H65 Bodmer, Immunotoxin treatment of Surface Antigen Knowles ICRF, Acute Graft versus Host (CD5) Licensed to Xoma Disease, Rheumatoid Corp. , USA) Arthritis. Infectious Agent-Related Antigens
  • Mumps virus- Anti-mumps Antibody conjugated to related polyclonal Diphtheria toxin for antibody treatment of mumps Mumps virus- Anti-mumps Antibody conjugated to related polyclonal Diphtheria toxin for antibody treatment of mumps.
  • the enzymatically active portion of the first component will be active in isolation from the cell-specific portion but it is necessary only for it to be enzymatically active when (a) it is in combination with the cell-specific portion and (b) the compound is attached to or adjacent target cells.
  • Antibodies with catalytic capacity have been developed (Tramontano et al Science 234. 1566- 1570) and are known as 'abzymes'. These have the potential advantage of being able to be humanized to reduce their immunogenicity.
  • the two portions of the first component of the kit of parts of the invention may be linked together by any of the conventional ways of cross-linking polypeptides, such as those generally described in O' Sullivan et al (1979) Anal. Biochem. 100, 100-108.
  • the antibody portion may be enriched with thiol groups and the enzyme portion reacted with a bifunctional agent capable of reacting with those thiol groups, for example the N- hydroxysuccinimide ester of iodoacetic acid (NHIA) or N-succinimidyl-3-(2- pyridyIdithio)propionate (SPDP).
  • NHS N- hydroxysuccinimide ester of iodoacetic acid
  • SPDP N-succinimidyl-3-(2- pyridyIdithio)propionate
  • Amide and thioether bonds for example achieved with m-maleimidobenzoyl-N-hydroxysuccinim ⁇ de ester, are generally more stable in vivo than disulphide bonds. It may not be necessary for the whole enzyme to be present in the first component (or the third component, if the third component metabolises the drug) of the kit of parts but, of course, the catalytic portion must be present.
  • said first component may be produced as a fusion compound by recombinant DNA techniques whereby a length of DNA comprises respective regions encoding the two portions of the compound of the invention either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the compound.
  • a length of DNA comprises respective regions encoding the two portions of the compound of the invention either adjacent one another or separated by a region encoding a linker peptide which does not destroy the desired properties of the compound.
  • the two portions of the compound may overlap wholly or partly.
  • the DNA is then expressed in a suitable host to produce a polypeptide comprising the compound of the invention.
  • the DNA encoding the polypeptide constituting the compound of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention.
  • Such techniques include those disclosed in US Patent Nos. 4.440,859 issued 3 April 1984 to Rutter et al. 4.530.901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crowl. 4,677,063 issued 30 June 1987 to Mark et al. 4,678,751 issued 7 July 1987 to Goeddel.
  • DNA encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host.
  • the companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.
  • the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression.
  • an expression vector such as a plasmid
  • the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the desired host, although such controls are generally available in the expression vector.
  • the vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells.
  • One selection technique involves inco ⁇ orating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.
  • Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide. which can then be recovered.
  • bacteria for example E. coli and Bacillus subtilis
  • yeasts for example Saccharomyces cerevisiae
  • filamentous fungi for example Aspergillus
  • plant cells animal cells and insect cells.
  • the vectors include a procaryotic replicon, such as the ColEl ori, for propagation in a procaryote, even if the vector is to be used for expression in other, non-procaryotic, cell types.
  • the vectors can also include an appropriate promoter such as a procaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as E. coli, transformed therewith.
  • a promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur.
  • Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.
  • Typical procaryotic vector plasmids are pUC 18, pUC 19, pBR322 and pBR329 available from Biorad Laboratories. (Richmond. CA. USA) and pTrc99A and pKK223-3 available from Pharmacia. Piscataway, NJ. USA . '
  • a typical mammalian cell vector plasmid is pSVL available from Pharmacia. Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS- 1 cells.
  • an inducible mammalian expression vector is pMSG. also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive expression of the cloned gene.
  • Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla. CA 92037. USA.
  • Plasmids ⁇ RS403, pRS404, pRS405 and ⁇ RS406 are Yeast Integrating plasmids (Yips) and inco ⁇ orate the yeast selectable markers his3, trpl, leu2 and ura3.
  • Plasmids pRS413-416 are Yeast Centromere plasmids (YCps)
  • a variety of methods have been developed to operatively link DNA to vectors via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.
  • Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors.
  • the DNA segment generated by endonuclease restriction digestion as described earlier, is treated with bacteriophage T4 DNA polymerase or E. coli DNA polymerase I, enzymes that remove protruding, 3 ' -single-stranded termini with their 3'-5'-exonucleol ⁇ tic activities, and fill in recessed 3 '-ends with their polymerizing activities.
  • the combination of these activities therefore generates blunt-ended DNA segments.
  • the blunt-ended segments are then incubated with a large molar excess of linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as bacteriophage T4 DNA ligase.
  • the products of the reaction are DNA segments carrying polymeric linker sequences at their ends.
  • These DNA segments are then cleaved with the appropriate restriction enzyme and ligated to an expression vector that has been cleaved with an enzyme that produces termini compatible with those of the DNA segment.
  • Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc, New Haven, CN, USA.
  • a desirable way to modify the DNA encoding the polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki et al (1988) Science 239, 487-491.
  • the DNA to be enzymatically amplified is flanked by two specific oligonucleotide primers which themselves become inco ⁇ orated into the amplified DNA.
  • the said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.
  • Exemplary genera of yeast contemplated to be useful in the practice of the present invention are Pichia, Saccharomyces, Kluyveromyces, Candida, Torulopsis, Hansenula, Schizosaccharomyces, Citeromyces, Pachysolen, Debaromyces, Metschunikowia, Rhodosporidium, Leucosporidium, Botryoascus, Sporidiobolus , Endomycopsis. and the like.
  • Preferred genera are those selected from the group consisting of Pichia, Saccharomyces, Kluyveromyces, Yarrowia and Hansenula.
  • Saccharomyces are Saccharomyces cerevisiae- Saccharomyces italicus and Saccharomyces rouxii.
  • Kluyveromyces are Kluyveromyces fragilis and Kluyveromyces lactis.
  • Hansenula are Hansenula polymorpha, Hansenula anomala and Hansenula capsulata.
  • Yarrowia lipolytica is an example of a suitable Yarrowia species.
  • Suitable promoters for S. cerevisiae include those associated with the PGK1 gene, GAL1 or GAL10 genes, CYC1, PH05, TRP ADH1. ADH2. the genes for glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, triose phosphate isomerase, phosphoglucose isomerase. glucokinase, ⁇ -mating factor pheromone.
  • a-mating factor pheromone the PRB1 promoter, the GUT2 promoter, and hybrid promoters involving hybrids of parts of 5' regulatory regions with parts of 5' regulatory regions of other promoters or with upstream activation sites (eg the promoter of EP-A-258 067).
  • the transcription termination signal is preferably the 3' flanking sequence of a eukaryotic gene which contains proper signals for transcription termination and polyadenylation.
  • Suitable 3' flanking sequences may, for example, be those of the gene naturally linked to the expression control sequence used, ie may correspond to the promoter. Alternatively, they may be different in which case the termination signal of the S. cerevisiae AHD1 gene is preferred.
  • the second component of the kit is a pro-drug which is relatively non-toxic, which is a substrate for the enzyme in the first component of the kit and which is converted to a cytotoxic substance.
  • the cytotoxic substance may be any existing anti cancer drug such as an alkylating agent, an agent which interca ⁇ lates in DNA. inhibits any key enzymes such as dihydrofolate reductase- thymidine synthetase, ribonucleotide reductase. nucleoside kinases or topoisomerase or effects cell death by interacting with any other cellular constituent. Etoposide is an example of a topoisomerase inhibitor.
  • the inactivating portion of the compound of the invention which forms the third component of the kit of parts must be chosen to suit the active drug that has been generated. It is also necessary for most of the inactivation of the cytotoxic drug to be confined to the vascular compartment so as to avoid undesirable inactivation of the active drug at target sites.
  • the inactivating portion of the compound does not inactivate the prodrug which may also be present in the blood, in such a way that its conversion into the cytotoxic drug is prevented. It is desirable to have prodrug in the blood so that it can reach tumour sites, where it is converted to the cytotoxic drug.
  • a means is therefore provided by which an active drug generated from a prodrug at particular sites in the body can be inactivated in the blood of a patient without comparable inactivation of any prodrug which is present in the blood.
  • the inactivating portion may be an enzymatically active portion, capable of converting the active drug into a less toxic substance. It may not be necessary for the whole enzyme to be present but, of course, the catalytic portion must be present.
  • the inactivating portion may be the enzyme carboxypeptidase G2 or another folate- deglutamating enzyme, which degrades methotrexate thereby inactivating it.
  • CPG 1 and CPG2 carboxypeptidase G I and G2 degrade folates including methotrexate by cleavage of the terminal glutamic acid.
  • the actions of the two enzymes are thought to be the same.
  • the following description of preferred aspects of the invention refers to CPG2 but is equally applicable to CPG 1 and to any other enzymes acting on the same substrates. and to abzymes acting on the same substrates.
  • carboxypeptidase G2 The isolation, purification and some of the properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16 have been disclosed by Sherwood et al (1984) Eur. J. Biochem. 148, 447-453.
  • CP2G2 is available from the Division of Biotechnology, Centre for Applied Microbiological Research, Porton Down, Salisbury. UK.
  • Carboxypeptidase G I (CPG 1 ) is disclosed by Chabner et al (1972) Cancer Res. 32, 21 14-21 19.
  • the inactivating portion may alternatively be a chemical moiety which reacts spontaneously with the active cytotoxic drug or does so more effectively in the presence of an appropriate catalyst.
  • the inactivating portion may comprise a thiol-containing substance and inactivation is catalysed by glutathione transferase carried in or on macromolecular entities.
  • the inactivating portion may alternatively, for example, be an antibody or part thereof which binds to the active drug, but not to the corresponding prodrug. or does so only to a more limited extent, or which is catalytically active towards the pro-drug thereby inactivating it. but not active towards the drug.
  • cytotoxic drugs may be facilitated by the well known technique of haptenisation, in which the low molecular weight molecule is conjugated to a highly immunogenic protein, such as keyhole limpet haemocyanin or other carrier molecule.
  • a highly immunogenic protein such as keyhole limpet haemocyanin or other carrier molecule.
  • prodrug is converted to active drug by catalytic cleavage of a moiety of the prodrug
  • the production of an antibody capable of discriminat ⁇ ing between prodrug and active drug is favoured since, in the prodrug, the non- active moiety can sterically inhibit binding of an anti-drug antibody to the thus hidden drug portion of the prodrug.
  • the inactivating portion may be conjugated to the restraining portion according to methods of linkage known in the art, thereby to retain the compound of the invention in the vascular compartment.
  • a further component may achieve accelerated clearance of antibody-enzyme conjugate and/or inactivation of the specific enzyme from non-tumour sites.
  • the antibody used for clearing or inactivating the antibody-enzyme conjugate can be directed towards the antigen binding site on the antitumour antibody, or the active site of the enzyme, or any other site on the antibody-enzyme conjugate.
  • Such antibodies may have additional galactose residues or other sugars added to accelerate clearance or may be desialylated.
  • Galactosylation of the antibody results in its rapid clearance from the blood through take-up by galactose receptors on hepatocytes.
  • the antibody- enzyme conjugate is galactosyiated, and given after the hepatic galactose receptors have been blocked by asialo-bovine submaxillary gland mucoprotein or antibody directed at hepatic galactose receptor or other molecule with high affinity for galactose receptor.
  • the blocking substance is maintained in plasma for a period of up to 24 hours so that the antibody-enzyme complex localises at tumour sites but following cessation of galactose receptor blockade, the galactosyiated antibody-enzyme is quickly cleared via the available galactose receptors.
  • a component may also be required to avoid the constraints which could be imposed by the host immune response to foreign proteins.
  • the nature of this component may change with the stage of development of methods of immuno- logical control.
  • Methods which can be used to overcome the host response to foreign protein are known in the art.
  • Techniques for reducing the immunogenicity of foreign proteins, applicable to antibody-enzyme conjugates, is that of conjugation to forms of polyethylene glycol (Wilkinson et al (1987) J. Immunol. 139, 326-331).
  • the problem ofimmunogenic ⁇ ty may be overcome by administering immunosuppressors or immune tolerance inducing agents. Cyclosporin and FK506 are widely used drugs to achieve immunosuppression in tissue transplantation.
  • Cyclosporin has been shown to delay host antibody respone to foreign protein (Lederman et al (1988) Br. J. Cancer 58, 562-566 and 654-657). Tolerance to foreign proteins when the host encounters the foreign problem for the first time after receiving an antibody directed at the CD4 epitope on lymphocytes has been disclosed (Waldman et al (1988) pp 16- 30 in Progress in Allergy (Shizata & Woksman. Eds, New York). Further means to achieve this have been described elsewhere and may change as improvements occur in control of host antibody responses to foreign antigens. Catalytic antibodies (abzymes) may be 'humanized' to reduce or remove their immunogenicity.
  • a fourth aspect of the present invention provides a method of destroying target cells in a host, the method comprising administration to the host of the various components described above.
  • the components of the invention are administered in any suitable way, usually parenterally, for example intravenously, intraperitoneally or intravesicallv, in standard sterile, non-pyrogenic formulations of diluents and carriers.
  • tumour concentration of the enzyme will be higher than in normal tissues, the volume of normal tissues is much greater.
  • haemopoietic function myelosuppression
  • a tumour target it is expected to be much less with the system described herein.
  • myelosuppression a much greater tumour effect is expected.
  • Growth factors or growth inhibitory factors acting on haemopoietic tissues may therefore be usefully employed in combination with the system described herein.
  • the system described herein may be used in conjunction with other forms of therapy. These include conventional cytotoxic agents, and use of multiple enzyme delivery to inactivate more than one metabolite.
  • an enzyme delivered to tumour sites by an antibody may function both to activate a pro-drug and to inactivate a metabolite which protects normal tissues.
  • Carboxypeptidase G2 as disclosed herein inactivates folinic acid at tumour sites to leave the tumour cells unprotected against trimetrexate.
  • the same tumour located enzyme can activate a benzoic acid pro-drug to form a cytotoxic mustard (as disclosed by Bagshawe (1989) Brit. J. Cancer 60. 275- 281).
  • Figure 2 shows the structures of (I) a pro-drug and (II) the cytotoxic drug (a benzole acid mustard) produced after cleavage of (I) with carboxypeptidase G2.
  • Figure 3 shows a scheme for conjugating aminobenzoic acid to keyhole limpet haemocyanin.
  • Figure 4 is a diagrammatic representation of the invention wherein the first component is a target-cell specific antibody coupled to carboxypeptidase A (CPA); the second component is alanine-methotrexate; and the third component is a restraining portion coupled to carboxypeptidase G2 (CPG2).
  • CPA carboxypeptidase A
  • CPG2 carboxypeptidase G2
  • the invention relates to a general principle and may be applied to other cytotoxic agents.
  • Example 1 A therapeutic system using Ala-methotrexate carboxypeptidases A and G2
  • methotrexate is a folic acid antagonist and its action is to block the conversion of folic acid, a dietary factor, to its reduced form 5- methyltetrahydrofolic acid (folinic acid, citrovorum factor) by the enzyme dihydrofoiate reductase.
  • Folinic acid is used in one carbon transfer in the synthesis of DNA. In the absence of folinic acid, cell reproduction is blocked in S phase and cell death follows.
  • Methotrexate is used in the treatment of a wide range of malignant diseases. It also causes cell death in normal cell renewal tissues via the mechanisms already outlined. The magnitude of its effects is largely a function of the duration of tissue exposure to the drug, the longer the duration the greater the toxic effect.
  • methotrexate Susceptibility to the action of methotrexate is thought to result from polyglutamation of the drug which, by delaying its breakdown within and its excretion from the cell, favours prolonged action.
  • the effect of methotrexate can be by-passed by folinic acid, generally given in the form of 5-formyl tetrahydrofolic acid.
  • Carefully timed and dose-controlled administration of methotrexate with folinic acid has been found advantageous over the use of methotrexate alone in the treatment of some cancers. Thus large doses of methotrexate are commonly followed after 12-24 hours by folinic acid 'rescue' .
  • the first component of the system of the present invention comprises an antibody or antibody fragment conjugated to carboxypeptidase A, directed at the tumour associated antigen, carcinoembryonic antigen.
  • Carboxypeptidase A is available from bovine and bacterial sources (for example from Calbiochem, Nottingham, UK) and is also present in human pancreas. The enzyme hydrolyses oligopeptides from the C terminal end of polypeptide chains, or from other compounds containing conjugated amino acids with a free carboxyl group. Carboxypeptidase A has a preference for aromatic residues. It is normally formed from mammalian sources by trypsinization of a complex assembly of three subunits produced by the pancreas.
  • a further component may achieve accelerated clearance or inactivation of carboxypeptidase A from non-tumour sites.
  • the second component is alanine methotrexate (Kuefner et at 1989) which is the prodrug from which the active drug methotrexate is generated by the action of carboxypeptidase A.
  • the third component is carboxypeptidase G2 conjugated to a macromolecular structure such as dextran-
  • the pu ⁇ ose of the macromolecule is to confine CPG2 activity to the vascular compartment.
  • CPG2 may be coupled to soluble dextrans (Lomodex 40. Lomodex 70, Dextraven 110 and Dextraven 150. all trade marks: Fisons. Loughborough, Leics., UK) according to the method of Melton et al (1987).
  • a volume of dextran prepartion containing 1 g of dextran in 0.9% NaCl was diluted to 100 ml with 0.9% NaCl and reacted with cyanogen bromide (CNBr; Sigma, Poole, Dorset, UK).
  • CNBr 0.5 g
  • the reaction mixture was vigorously stirred at room temperature and maintained at pH 10.7 ⁇ 0.1 units in a pH-stat (Radiometer. Copenhagen, Denmark) by addition of 2 M NaOH.
  • the CNBr was added as a finely divided powder in two equal portions at an interval of 20 min; the second portion was allowed to react until the pH of the reaction mixture was stable at 10.7; the pH was then adjusted to 9.0 and the mixture dialysed against running water for 2 hr at 4°C.
  • the pH was brought back to 9.0 with 1 M NaOH and 1 ml enzyme solution (1265 U; 2.3 mg) in 0.1 M Tris-HCl buffer, pH 7.3, was added.
  • the mixture was reacted overnight at 4°C after which 0.25 g glycine was added to block excess reactive sites.
  • the mixture was stirred for a further 30 min and then concentrated to a volume of 40 ml in a model 202 concentrator using a PM 10 ultrafiltration membrane (Amicon, Stonehouse. UK).
  • the mixture (40 ml) was then chromatographed on a 1 .3 litre bed volume of Sephadex G 150 in a 4.4 x 87 cm column (Pharmacia, Uppsala, Sweden) and eluted with 0.05 M potassium phosphate buffer, pH 7.0.
  • the peak fractions were pooled and concentrated to a volume of 10-12 ml as before. Enzyme activity and carbohydrate content were determined and protein content measured by the Coomassie blue method (M.M. Bradford (1976) Analyt. Biochem. 72, 248) using bovine serum albumin fraction V as standard in the range 0-100 ⁇ g/ml.
  • the concentrated material was filter sterilised (Millipore "Millex GS n , 0.22 ⁇ m pore size) and stored at -20°C. Millex GS is a trade mark.
  • the antibody-carboxypeptidase A conjugate if comprising antibody of murine origin and enzyme of bovine origin, would be immunogenic.
  • a carboxypeptidase G2 macromolecule conjugate would also be immunogenic since CPG2 is bacterial in origin. It may be desirable, therefore, to reduce their immunogenicity or to employ means to induce immunosuppression or immune tolerance.
  • Administration of a component capable of overcoming the host response to foreign protein may be started 48 hours before administration of Component 1. Initial tests may be performed to exclude as far as possible abnormal reaction by the patient to any of the protein components.
  • the antibody-CPA conjugate is given intravenously, preferably by slow infusion, typically over 2 hours. Maximal tumour concentration of the antibody-CPA conjugate is achieved several hours later but at this time there are still high levels of CPA activity in plasma. It is desirable to eliminate this activity as far as possible before administering the prodrug. This elimination process is achieved by administra ⁇ tion of a component capable of achieving accelerated clearance or inactivation of CPA from non-tumour sites.
  • This component is administered intravenously over several hours, typically 6-24 hours, or until enzyme is no longer detectable in plasma and may be infused at low concentration throughout the period of pro-drug administration. During this time enzyme in extracellular fluid diffuses back into the plasma as the plasma level of the enzyme falls. Tests for enzyme activity from plasma are continued for a period typically 8-24 hours to ensure that plasma CPA activity is not detectable. More of said component which eliminates the CPA activity is given if necessary. Alternative methods of accelerated clearance have been described.
  • Administering component 3 is then commenced either by a series of bolus injections or by slow infusion.
  • components 2 and 3 are started simultaneously (ie the pro ⁇ drug and the inactivating compound).
  • Pro-drug may be given as a series of bolus injections or by continuous infusion.
  • Administration of components 2 and 3 will normally continue for about 4-7 days but specific embodiments of Component 1 may ensure that sufficient enzyme actively persists at tumour sites for somewhat longer periods.
  • component 2 is discontinued, component 3 may be discontinued.
  • Component 1 is reinfused as previously, followed by the component which eliminates the plasma CPA activity as previously. Similar procedures to those previously described are followed before recommencing component 2.
  • the cycle may be repeated. Limiting factors will be toxicity attributable to alanine methotrexate or the development of host antibodies to any of the foreign proteins employed.
  • these agents differ from natural folates and methotrexate with respect to substitution for instance at the N 10 position and in the benzoyl ring but like natural folates and methotrexate have a terminal glutamate moiety linked to the benzoyl ring. Therefore at least some of the drugs in this series are inactivated by a peptide substitution such as an alanine In the position of the glutamate, and that such alanine- or other peptide-substituted derivatives are synthesized using the methodology described by Kuefner et al e. cit. or variations thereof known in the art.
  • quinazoline antifolates are deglutamated, and therefore inactivated, by carboxypeptidase G2 or a similar enzyme.
  • carboxypeptidase G2 or a similar enzyme.
  • These compounds are of particular interest because they act by inhibition of thym ⁇ dylate synthetase.
  • the chemical application of such drugs may be greatly extended by being administered in pro-drug form, converted to the active compound by carboxypeptidase A and the active drug in plasma degraded by carboxypeptide G2.
  • benzoic acid itself is not large enough to be immunogenic. It was considered that the most effective method of raising antibodies specific for the acid region would be to inoculate animals with a benzoic acid analogue that had been previously conjugated to Keyhole Limpet Haemocyanin (KLH).
  • KLH Keyhole Limpet Haemocyanin
  • a compound was svnthesised that consisted of an L-lysine amino acid linked through an amide bond to aminobenzoic acid (VII). Then (VII) was conjugated to KLH by conventional methods using the e-NH 2 groups on the Iys ⁇ ne portion of the molecule, to produce the specific immunogen (VIII).
  • the conjugate was suspended in saline (0.9%) to a final concentration of I mg/ml.
  • the suspension was then emulsified in Freund's adjuvant (Complete or Incomplete), prior to inoculation. 20
  • the ADEPT concept uses an antibody-enzyme conjugate to generate a cytotoxic drug from an inactive precursor at tumour sites.
  • the present invention is used in conjuction with ADEPT. Active drug is generated at the tumour site using the ADEPT antibody-enzyme conjugate. Any active drug entering the blood compartment is cleared from the blood using the inactivating agent coupled to the restraining portion.
  • nude mice bearing human choriocarcinoma (CC3) tumours received 29 units of CPG2 conjugated to anti-HCG (W 14 Fab 2 , as disclosed in WO 88/07378). and after 24 or 48 hours received pro-drug (41 ⁇ M/kg). The amount of inactivating agent is adjusted to give an optimal protective effect.
  • Example 6 Preparation of a monoclonal antibody reactive against carci ⁇ oembrvonic antigen
  • Purified CEA was prepared from metastases of colonic tumour. Radio- iodination to a specific activity of 6 ⁇ Ci ⁇ g " 1 was carried out by the iodogen method. Dilution buffer was prepared as a 0. 15M sodium phosphate buffer. pH 7.4, containing 0.1 % bovine serum albumin. The studies at low ionic strength were carried out in 0.02M Tris-HCl buffer at pH 7.4.
  • Spleen cells from the immunised mice were then fused with either SP2/0-Ag 14 or P3-NS/l-Ag 4-1 myeloma cells (Flow Laboratories. UK) and the hybridomas producing anti-CEA cloned by single cell transfer.
  • the monoclonal anti-CEA (A 5 B 7 ) used in this study has been described previously and chosen for its low cross-reactivity with NCA and its stability on immunopurification and radiolabelling.
  • F(ab') 2 fragments were prepared by the method Lamoyi and Nisonoff (1983) J. Immunol. Methods 56, 235-243. After separation of the digest mixture on Sephacryl S-200, the fractions were analysed by SDS-PAGE using a 7.5% gel. The fraction containing the F(ab') 2 was concentrated and dialysed against 0.15M phosphate buffer. pH 7.
  • a monoclonal antibody raised against carboxypeptidase is used for making bispecific antibody (see next Example) and for clearance and inactivation of residual enzyme activity at non-tumour sites.
  • the monoclonal antibody was made in the following way.
  • Balb/C mice (6-8 weeks old) were immunised with 50 ⁇ g CPA i.p. in incomplete Freund's adjuvant followed by two injections of CPA in complete Freund's adjuvant (50 ⁇ g CPA each, i.p.) at monthly intervals and with two daily injections (50 ⁇ g and 100 ⁇ g in PBS. i.v.) 2 days before fusion.
  • Immune spleen cells were fused with non-immunoglobulin secreting SP2/0 myeloma cells according to the hybridoma procedures of K ⁇ hler and Milstein (1975).
  • the presence of anti-CPA antibodies was detected by a solid-phase indirect radioimmunoassay.
  • a 1 ⁇ g ml "1 solution of CPA in 0.05 M phosphate buffer was placed in polyvinyl microtitre plates (100 ng per well), allowed to dry. fixed with methanol and washed with PBS buffer containing a 0.05 % Tween and 0. 1 % bovine serum aibumin.
  • Supernatant or purified antibody samples were diluted in PBS and incubated in the CPA coated microtitre plates (100 ⁇ l per well) at 37 °C for 4 h and then for 1 h with 125 I-labelled rabbit anti-mouse IgG.
  • the wells were washed three times with PBS-Tween buffer between each stage and after final washing individual wells were cut and counted in a gamma counter.
  • the hybridoma producing A 5 B 7 a monoclonal antibody reactive against CEA has been disclosed by Harwood et al (1986) Brit. J. Cancer 54, 75-82. and a method of generating a hybridoma, a monoclonal antibody reactive against CPA is disclosed in Example 8.
  • the fusion protocol allows any two antibody-producing hybridomas to be fused and has been diclosed previously (Clark & Waldmann (1987) J. Natl. Cancer Inst. 79, 1393-1401).
  • 5 x 10 6 to 3.5 x 10 7 cells of one parental hybridoma that have been previously renderedhypoxanthine/aminopterin/- thymidine (HAT) sensitive by selection for a hypoxanthine phosphoribosyltransferase-negative variant were fused at 1 1 : 1 or 10: 1 ratio. using 1 ml of a 50% (wt/vol) solution of polyethylene glycol.
  • hybrid hybridomas were selected for in medium containing HAT.
  • Example 10 Reduction of residual enzvme activity at non-tumour sites
  • a monoclonal antibody directed at CPA inactivates the enzyme.
  • additional galactose residues are conjugated to it so that it can still inactivate enzyme in plasma when it is given by intravenous route but the inactivating antibody is rapidly removed from the plasma and galactose receptors on hepatocytes.
  • the galactosyiated anti-CPA monoclonal antibody is given to eliminate enzymic activity in plasma and then to give an amount of the non-galactosylated anti- CPA monoclonal antibody to inactivate residual enzyme activity in other non- tissues.
  • the monoclonal antibody is galactosyiated using the following protocol: A stock solution of the activated derivative was made up as follows: Cyanomethyl 2,3,4,6-tetra-0-acetyl-l-thio-/3-D-galactopyranoside (Sigma C- 4141) [400 mg] in anhydrous methanol (10 ml) was treated with 5.4 mg of sodium methoxide in 1 ml of anhydrous methanol at room temperature for 48 hours. The mixture was kept in a 25 ml Quickfit conical flask fitted with a slightly greased stopper.
  • a stock solution of monoclonal antibody (1.3 mg/ml) is prepared in 0.25 M sodium borate buffer, pH 8.5. Aliquots of the required amount of activated galactosyl derivative (80. 40, 20. 10 ⁇ l) are dispensed into 3 ml glass ampoules and evaporated to a glassy residue in a stream of nitrogen. A solution of the antibody (200 ⁇ g) is added mixed until the residue is dissolved. After 2 hours at room temperature, the solution is dialysed against three changes of PBS.
  • the preparations are scaled up by taking multiples of the volumes mentioned above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On décrit un ensemble de trois composants destinés à être utilisés dans un procédé de destruction de cellules cibles chez un hôte. Le premier composant comprend une partie spécifique de cellule cible et une partie enzymatiquement active pouvant transformer un promédicament cytotoxique en un médicament cytotoxique. Le second composant est un promédicament cytotoxique transformable par la partie enzymatiquement active du médicament cytotoxique. Le troisième composant comprend une partie pouvant au moins empêcher partiellement le composant de quitter le compartiment vasculaire d'un hôte lorsque ledit composé est administré dans le compartiment vasculaire, et une partie d'inactivation pouvant transformer le médicament cytotoxique en une substance moins toxique.
PCT/GB1993/000040 1992-01-09 1993-01-11 Inactivation de medicaments cytotoxiques WO1993013806A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9410237A GB2276624B (en) 1992-01-09 1993-01-11 Inactivation of cytotoxic drugs in the vascular compartment of a host
EP93901821A EP0620742A1 (fr) 1992-01-09 1993-01-11 Inactivation de medicaments cytotoxiques
JP5512252A JPH07506339A (ja) 1992-01-09 1993-01-11 細胞毒性薬剤の不活性化

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9200415.9 1992-01-09
GB929200415A GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9204104.5 1992-02-26

Publications (1)

Publication Number Publication Date
WO1993013806A1 true WO1993013806A1 (fr) 1993-07-22

Family

ID=26300132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/000040 WO1993013806A1 (fr) 1992-01-09 1993-01-11 Inactivation de medicaments cytotoxiques

Country Status (5)

Country Link
EP (1) EP0620742A1 (fr)
JP (1) JPH07506339A (fr)
CA (1) CA2124217A1 (fr)
GB (3) GB9200415D0 (fr)
WO (1) WO1993013806A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612240A4 (fr) * 1991-11-12 1995-05-17 David M Long Jr Procede servant a prolonger le temps de sejour vasculaire d'agents therapeutiques et diagnostiques particulaires.
WO1995013095A3 (fr) * 1993-11-12 1995-07-13 Wellcome Found Therapie
WO1998024478A3 (fr) * 1996-11-30 1998-07-30 Aepact Ltd Therapie tumorale
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
FR2883873A1 (fr) * 2005-03-31 2006-10-06 Pharmamens Sarl Inhibiteurs d'age
US9359439B2 (en) 2010-08-10 2016-06-07 Glycotope Gmbh Fab-glycosylated antibodies
US11872289B2 (en) 2018-05-18 2024-01-16 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061406A2 (fr) * 1998-05-22 1999-12-02 Abbott Laboratories Medicament anti-angiogenique pour le traitement du cancer, de l'arthrite et de la retinopathie
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US7732309B2 (en) * 2006-12-08 2010-06-08 Applied Materials, Inc. Plasma immersed ion implantation process

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (fr) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
EP0308208A1 (fr) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Anticorps conjugués modifiés en vue d'une élimination augmentée
WO1989010140A1 (fr) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Nouvelles ameliorations relatives a des systemes d'administration de medicaments
WO1990010460A1 (fr) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Procede de reduction des effets secondaires d'un medicament
WO1991009134A1 (fr) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Anticorps biospecifique des cellules cancereuses et enzyme presentant des caracteristiques d'activation promedicamenteuse
EP0506124A1 (fr) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Méthodes et produits pour diriger des agents thérapeutiques vers des tissus solides comprenant deux molécules de liaison bifonctionnelles VH-VL monocaténaires

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4905949A (en) * 1989-02-13 1990-03-06 Cosgrove James H Device for releasably supporting a plurality of objects

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007378A1 (fr) * 1987-03-09 1988-10-06 Cancer Research Campaign Technology Ltd. Amelioration apportees a des systemes d'administration de medicaments
EP0308208A1 (fr) * 1987-09-14 1989-03-22 Center For Molecular Medicine And Immunology Anticorps conjugués modifiés en vue d'une élimination augmentée
WO1989010140A1 (fr) * 1988-04-22 1989-11-02 Cancer Research Campaign Technology Limited Nouvelles ameliorations relatives a des systemes d'administration de medicaments
WO1990010460A1 (fr) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Procede de reduction des effets secondaires d'un medicament
WO1991009134A1 (fr) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Anticorps biospecifique des cellules cancereuses et enzyme presentant des caracteristiques d'activation promedicamenteuse
EP0506124A1 (fr) * 1991-03-27 1992-09-30 Tanox Biosystems, Inc. Méthodes et produits pour diriger des agents thérapeutiques vers des tissus solides comprenant deux molécules de liaison bifonctionnelles VH-VL monocaténaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Vol. 109, No. 17, Columbus, Ohio, US., J. BARBET et al., "Specific Toxicity to Activated T and B Lymphocytes of a Ricin A Immunotoxin Directed Against the Class I MHC Antigen, H-2 K", Abstract No. 142106q; & ANTIBODY, IMMUNOCONJUGATES, RADIOPHARM., Vol. 1, No. 2, 1988, pages 169-180. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 80, May 1983, G.W. YU et al., "Model for Specific Rescue of Normal Hepatocytes During Methtrexate Treatment of Hepatic Malignancy", pages 3078-3080. *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612240A4 (fr) * 1991-11-12 1995-05-17 David M Long Jr Procede servant a prolonger le temps de sejour vasculaire d'agents therapeutiques et diagnostiques particulaires.
US5679394A (en) * 1991-11-12 1997-10-21 Long, Jr.; David M. Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
WO1995013095A3 (fr) * 1993-11-12 1995-07-13 Wellcome Found Therapie
US6140100A (en) * 1993-11-12 2000-10-31 Glaxo Wellcome Inc. Cell-targeting molecule comprising a mutant human carboxypeptidase A
US6319702B1 (en) * 1993-11-12 2001-11-20 Glaxo Wellcome, Inc. Nucleic acids encoding mutant human carboxypeptidase A enzymes
WO1998024478A3 (fr) * 1996-11-30 1998-07-30 Aepact Ltd Therapie tumorale
US6867231B1 (en) 1997-06-14 2005-03-15 Enzacta R & D Limited Therapeutic systems
US7138122B2 (en) 1997-06-14 2006-11-21 Enzacta R & D Limited Therapeutic systems
FR2883873A1 (fr) * 2005-03-31 2006-10-06 Pharmamens Sarl Inhibiteurs d'age
US9512176B2 (en) 2005-03-31 2016-12-06 Centre National De La Recherche Scientifique Age inhibitors
US9359439B2 (en) 2010-08-10 2016-06-07 Glycotope Gmbh Fab-glycosylated antibodies
US11872289B2 (en) 2018-05-18 2024-01-16 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
US12291577B2 (en) 2018-05-18 2025-05-06 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
US12297289B2 (en) 2018-05-18 2025-05-13 Glycotope Gmbh Anti-MUC1 antibody

Also Published As

Publication number Publication date
GB9204104D0 (en) 1992-04-08
CA2124217A1 (fr) 1993-07-22
GB2276624B (en) 1995-10-25
GB2276624A (en) 1994-10-05
JPH07506339A (ja) 1995-07-13
GB9410237D0 (en) 1994-07-27
GB9200415D0 (en) 1992-02-26
EP0620742A1 (fr) 1994-10-26

Similar Documents

Publication Publication Date Title
US6299876B1 (en) Cytotoxic drug therapy
Melton et al. Antibody-enzyme conjugates for cancer therapy
JP4255512B2 (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
US5683694A (en) Method for the treatment of tumors with conjugated antibody A5B7 and a prodrug
US5973116A (en) Compounds for targeting
US6361774B1 (en) Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
WO1993013806A1 (fr) Inactivation de medicaments cytotoxiques
Bagshawe Antibody-directed enzyme prodrug therapy (ADEPT)
EP0918545B1 (fr) Therapie tumorale
WO1997024143A1 (fr) Agents cytotoxiques
Hay et al. Antibody-directed enzyme-prodrug therapy (ADEPT)
WO1997020580A1 (fr) Traitement medicamenteux
US20020131973A1 (en) Cytotoxic agents
GB2300859A (en) Compounds comprising a target cell-specific portion (TCP) and a cytotoxic portion (CP)
US20020127229A1 (en) Tumour therapy
AU6147599A (en) Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA GB JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1993901821

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2124217

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 1994 256382

Country of ref document: US

Date of ref document: 19940708

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993901821

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993901821

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993901821

Country of ref document: EP